Thursday, May 17, 2012

The New Barbarians are at the Gate

The Secret Biotech Abstracts Get Released Today 

Get ready. Today at 6 pm, the leading oncological group in America releases abstracts on the world's most promising cancer drugs. Every year, investors pound these special listings... and a buying frenzy ensues. As a result, a large handful of cheap biotechs see their prices soar, giving early investors whopping gains. But today you'll have an opportunity to get in hours before everyone else. You see, Bill Patalon has already done the research. And right now he's identifying three small companies with the potential for near-vertical spikes. Just go here. 

May 16, 2012

The New Barbarians are at the Gate 

[Editor's Note: As Shah wrote in Part One, "Your future is calling and the ringtone sounds like a cash register." Below is the second installment in this four-part series on mobile wallet technology. I hope you enjoy it.

By Shah Gilani, Capital Waves Strategist

As I discussed in Part One, the sky is the limit when it comes tomobile wallet technology.

The big brand credit card issuers: American Express, MasterCard, Visa, and Discover Card, along with every other card issuer and wannabe credit extension intermediary are all already into the mobile wallet space.

Their offerings vary and competition between them will be as brutal as it always has been. And that's good for consumers.

Creating choices for consumers to drive business will lead to more innovation and more services offered at more competitive prices. At least, that's the way the free market is supposed to work.

But, traditional credit card issuers that are forcing banks to compete to offer credit to card borrowers, aren't the "disintermediators" I talked about in Part One.

They help spread banking relationships across the spectrum, they do not remove banks from the equation. And because banks are all in the present equation, pricing pressures aren't prevalent and fees and costs remain stubbornly high.

But as you'll see, that's about to change.

The Greater Fear for the Banks

What banks fear most in the burgeoning mobile wallet world are New Barbarians breaking down the gates that traditionally walled off banks from meaningful interlopers.

The biggest, baddest New Barbarians at the gate are some of the biggest names in the Internet world, the social media world, and the telecom world.

If you want to make a fortune on the mobile wallet future the giant players and Barbarian disintermediators to watch and invest in include: GoogleYahoo (yes, Yahoo), Microsoft (believe it or not),Facebook (when it goes public), Nokia, Research in Motion (yes, I am advocating buying Nokia and RIMM), Apple, Verizon, and Vodafone.

There will be other giants worth buying, but until the ground shakes from their emergence, these giants have a giant head start in the mobile wallet world of the future, starting now.

Of course, keep in mind that the scope of this series is intentionally broad.

So, it's not the place to give specific reasons to buy specific companies. My purpose is to explain to readers the extraordinary opportunities inherent in the mobile wallet future.

But, if you want to know why these specific companies will be huge winners in mobile transactions and what they are doing to warrant their own exceptional futures, as well as when you should buy them, take heart. Keep reading Money Morning.

As it takes shape I will follow this report with specific recommendations accompanied by all the reasons and metrics you'll need to make informed investment decisions.

In the meantime, here's why these businesses are primed to rake in profits on the digital wallet phenomenon.

To subscribe to Shah's free newsletter, Wall Street Insights & Indictments and to continue reading click here...
-------------------------------------------------------------------------------------------------
The Top 10 Stocks for May 2012 

From the research team that's beat the market 7 out of the last 9 years... comes their report, The Top 10 Stocks for 2012. See why they think these picks will beat the stock market again in 2012... and beyond.
------------------------------------------------------------------------------------------------
Five with Fitz: What I See When I Look Over the Horizon 

By Keith Fitz-Gerald, Chief Investment Strategist

When you've been working the markets as long as I have, you learn that the biggest dangers are always found in a place just over the horizon.

It's why I spend my time hunting for stories, news items and opinions that in the old days were considered far "below the fold."

Invariably, what I am looking for is the stuff that everybody else has missed.

Because I believe that's where the real information is -- especially when it comes to uncovering profitable opportunities others don't yet see or understand.

It's the story behind the story that interests me. To find it, you need to go beyond the headline news.

In that spirit, here's my take on five things that I'm thinking about right now.

To continue reading, please, click here... 


The Single Best Profit Opportunity Right Now

Some of the most lucrative blockbuster drugs are coming "off patent" - meaning the companies making those drugs face a $170 billion loss in annual sales.

But there's a secret that Wall Street investment pros hope the little guy never learns.

The very same problem that has Big Pharma execs wringing their hands is also creating one of the biggest profit opportunities we've seen in years.

You see, these major drugmakers need replacement blockbusters. They're sniffing out the small players that are already developing the new potential blockbusters and either buying the drug, or buying the company outright.

Our research recently showed readers gained up to 103.5% on one of these "buyout biotechs."

But we're just getting started.

We've pinpointed exactly who will be among the next biggest winners. You can learn their names by clicking here.

How to Ride the Surge in Biotech Mergers & Acquisitions 

By Don Miller, Contributing Writer 

Innovations in biotechnology are evolving at the speed of light.

In fact, astonishing advancements in biotech have transformed the way we practice medicine. Leading-edge biotech products and breakthroughs are literally saving thousands of lives every day.

Needless to say, biotech stocks can be strong medicine for investors, too.

For instance, the Nasdaq Biotechnology Index rose 457% from the end of August 1998 to the end of February 2000. Going back even further to the early 1990s, biotech stocks have soared by 1,347%.

Think about it... for biotech investors every $10,000 invested turned into nearly $140,000.

The good news for investors is that after slumping during the recession, biotech stocks are making a comeback. In the first quarter of 2012 alone, the Nasdaq Biotech Index gained 18.2%

And conditions are setting up for even better gains in the future.

Here's why...

To continue reading, please click here...

No comments: